Sanifit logo portada

A new approach to
calcification disorders

Sanifit logo portada

A new approach to
calcification disorders

sanifit

SANIFIT

Sanifit is a biopharmaceutical company focused on treatments for calcification disorders, with SNF472 as the lead compound. The company was founded in 2007 as a spin-off from the University of the Balearic Islands, and has offices in Palma (Spain) and San Diego (USA). SNF472 is an experimental drug in development for the treatment of cardiovascular diseases related to calcification in the End Stage Renal Disease (ESRD) population undergoing hemodialysis. In 2018 Sanifit has completed a phase II proof of concept trial in patients with calciphylaxis, which met its primary endpoint.  The company is planning to initiate a phase III study in this orphan disease in 2018. The ongoing phase IIb study (Calipso) in ESRD patients on dialysis is evaluating the effect of SNF472 on progression of arterial calcification.

ABOUT US

PROJECT SUPPORTED BY

OVERVIEW PIPELINE

THERAPEUTIC PIPELINE

OTC PIPELINE

LATEST NEWS

  • Sanifit to present at the 2018 European Biotech Investor Day in New York City

      Palma, Spain and San Diego, USA, July 17, 2018 – Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, will present at the European Biotech Investor Day in NYC, organized by Solebury Trout, Goodwin LLC and Nasdaq. Sanifit will present at 3.00 PM on Thursday, July 19. Dr Joan Perelló, […]

  • Sanifit Presents Results from Phase 2 Clinical Trial of SNF472 at ERA-EDTA Congress

    Palma, Spain and San Diego, USA 25th May 2018 – Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, announced that the results of its Phase 2 clinical trial of SNF472 were presented during an oral session earlier today at the 55th ERA-EDTA Congress taking place in Copenhagen, Denmark. The presentation […]

  • Sanifit is delighted to Announce that Dr Joan Perelló has been granted the “CEO Today Europe Award”

    The international magazine CEO Today has published a list with the 100 Europe’s most talented Chief Executive Officers whose commitment to excellence and achievements are worth cheering for. Every year CEO Today Magazine identifies and honors the most progressive, forward-thinking and ambitious company leaders in todays’ business. The CEO Today team collate votes and in-depth […]

  • Sanifit Announces Results of the Phase II Clinical Trial of SNF472 in Patients with Calciphylaxis

    Palma, Spain and San Diego, USA March 06, 2018 – Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, announced today the completion of its Phase II clinical trial of SNF472, its lead candidate for the treatment of the orphan disease calciphylaxis (calcific uraemic arteriolopathy, CUA), with both primary and secondary […]

  • Sanifit announces the appointment of Cris Calsada as Chief Financial Officer

    Palma, Spain, and San Diego, USA, January 8, 2018 – Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today announced the appointment of Cris Calsada as Chief Financial Officer. Ms. Calsada joins Sanifit with over 20 years of corporate finance and executive experience in the life sciences and technology industries. […]

Your name (required)

Phone (required)

Company

E-mail (required)

Comments

CONTACT

Sanifit


SPAIN
ParcBIT – Ctra Valldemossa km7.4
Building Europa, 2nd floor
07121 Palma

 

 +34 971 439 925
 info@sanifit.com

USA
3655 Nobel Drive
Suite #540
San Diego, CA 92122